KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison.

Naveen Pemmaraju, Alessandro Lucchesi, Stephen T Oh, Koo Wilson, Zalmai Hakimi, Sarah A Buckley, Purvi Suthar, Mikolaj Parkitny, Piotr Wojciechowski, Klaudia Kolonko, John O Mascarenhas

Expert Rev Hematol 1-9

PMID42316774
PMCID-
DOI10.1080/17474086.2026.2686813
发表日期2026-06-19
AI 判定该论文不进入自动 KM 提取:This is a matching-adjusted indirect treatment comparison (MAIC) of existing trials, not a primary Phase III randomized controlled trial itself.
摘要

摘要

BACKGROUND: Thrombocytopenia is a prognostic marker in patients with myelofibrosis, associated with increased morbidity and reduced survival. We conducted a matching-adjusted-indirect-comparison (MAIC) of pacritinib-vs-momelotinib for treatment of patients with thrombocytopenic myelofibrosis. RESEARCH DESIGN AND METHODS: Data were from Phase 3 randomized controlled trials of patients with thrombocytopenic myelofibrosis treated with pacritinib 200 mg BID (PERSIST-2 [NCT02055781]) with baseline platelet count 24‒99 × 109/L matched on prognostic indicators with patients on momelotinib 200 mg QD (pooled post-hoc analysis of patients with platelet count <100 × 109/L (MOMENTUM [NCT04173494]; SIMPLIFY-1 [NCT01969838]). Week-24 endpoints included % patients achieving: ≥50% total symptom score reduction (TSS-50), ≥35% spleen volume reduction (SVR-35) and red-blood-cell-transfusion-independence (RBC-TI). Reweighted effects were compared with momelotinib using logistic regression/odds ratio (OR [95% confidence interval, CI]) and Cox regression/hazard ratio (HR [95% CI]) for overall survival (OS). RESULTS: After matching, baseline characteristics balanced; 76‒81% of matched pacritinib patients had moderate thrombocytopenia (platelet count 50‒99 × 109/L). All outcomes favored pacritinib on ORs (95% CI) for TSS-50: 1.75 (0.60, 5.09); SVR-35: 1.40 (0.32, 6.04); RBC-TI: 1.19 (0.36, 3.97); and OS: HR (95% CI) 0.35 (0.12, 1.05); however, none had statistical significance. CONCLUSIONS: This MAIC revealed consistent, nominal trends toward pacritinib efficacy benefits and OS in patients with myelofibrosis, most with moderate thrombocytopenia.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。